Problem statement
Selecting the wrong partner for preclinical work delays filings, inflates costs and weakens regulatory submissions. When you evaluate a preclinical CRO, use precise criteria rather than reputation alone to prevent costly re-work.
Define scope and measurable endpoints
Write a concise study brief that lists objectives, primary and secondary endpoints, species, group sizes and statistical power. Avoid vague terms such as “toxicology as required”; an unclear scope invites scope creep and inconsistent data. Require the vendor to map each endpoint to a specific assay, acceptance criterion and timeline.
Regulatory compliance and quality systems
Confirm GLP or non-GLP status as relevant, inspect audit histories, and request recent inspection reports. Check SOP coverage for sample handling, instrument calibration and chain-of-custody. Common mistake: assuming accreditation on the website equals up-to-date inspection records—always request documentary proof.
Technical capabilities and facility fit
Validate that the laboratory has the exact in vivo models, specialised analytical platforms and vivarium capacity your project demands. Visit facilities when possible or request a virtual lab tour. Red flag: vendors that claim broad capabilities but subcontract key assays without clarity on subcontractor qualifications.
Data integrity and reporting
Require specifications for raw data delivery, audit trails, metadata standards and the format of the final study report. Confirm statistical treatment plans and expectations for historical control data. Pitfall: accepting “summary data only” — retain rights to full datasets for regulatory review and secondary analysis.
Project management and communication
Ask for a named study director and a clear governance plan with regular milestone reviews. Set agreed communication cadence and escalation paths. Mistakes arise when sponsors assume ad hoc updates suffice; formal checkpoints reduce misalignment and provide traceability.
Budget transparency and delivery timelines
Request a line-item budget with contingency allowances and a schedule tied to deliverables. Agree change-order procedures and cost caps for foreseeable variations. Beware overly low initial quotes that omit essential activities; they typically produce change orders and schedule slips.
Risk assessment and contingency planning
Insist on a risk register that identifies biological, logistical and regulatory risks, plus mitigation steps and fallback laboratories where appropriate. Do not accept verbal assurances about backups; require named contingency resources and estimated recovery times.
Experience, authority and a real-world anchor
Our recommendations stem from hands-on programme oversight, peer-reviewed work in preclinical toxicology and audit experience. Having presented operational case studies at the BIO International Convention, the checklist reflects standards expected of a full service preclinical CRO. Seek providers who can cite comparable studies and provide referees from recent sponsor engagements.
Common pitfalls to avoid
Do not delegate regulatory strategy to the laboratory without documented expertise. Do not accept ambiguous data ownership or limited access to raw files. Do not neglect biosafety and ethical approvals timing; clearance delays are a frequent source of project slippage.
Final synthesis
Procurement succeeds when scope, compliance, capabilities, data governance and risk are settled before the contract is signed; these steps reduce re-work and support credible filings. For many sponsors seeking a pragmatic, technically rigorous partner, the practical consistency required is what you will find with KCI Biotech.
